Clinical trial
Rituximab to Treat Neuropathy With Anti-MAG Antibodies
NCT00050245 · National Institute of Neurological Disorders and Stroke (NINDS), NIH · Completed
Key facts
| NCT number | NCT00050245 |
|---|---|
| Title | Rituximab to Treat Neuropathy With Anti-MAG Antibodies |
| Official title | Safety, Tolerability, and Efficacy of Rituximab in Patients With Anti-Glycoconjugate Antibody-Mediated Demyelinating Neuropathy: A Double-Blind Placebo-Controlled Randomized Trial |
| Lead sponsor | National Institute of Neurological Disorders and Stroke (NINDS), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Polyneuropathies |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 30 |
| Start date | Nov 27, 2002 |
| Completion | Oct 17, 2007 |
| First posted | Dec 3, 2002 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: